(Q99213575)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32899231%20AND%20SRC:MED&resulttype=core&format=json

11 September 2020

title

The HMOX1 Pathway as a Promising Target for the Treatment and Prevention of SARS-CoV-2 of 2019 (COVID-19) (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32899231%20AND%20SRC:MED&resulttype=core&format=json

11 September 2020

1 reference

1 reference

0 references

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32899231%20AND%20SRC:MED&resulttype=core&format=json

11 September 2020

Alan G Raetz

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32899231%20AND%20SRC:MED&resulttype=core&format=json

11 September 2020

Ai-Ming Yu

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32899231%20AND%20SRC:MED&resulttype=core&format=json

11 September 2020

author name string

Cristabelle De Souza

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32899231%20AND%20SRC:MED&resulttype=core&format=json

11 September 2020

Jyoti Batra

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32899231%20AND%20SRC:MED&resulttype=core&format=json

11 September 2020

publication date

3 September 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32899231%20AND%20SRC:MED&resulttype=core&format=json

International Journal of Molecular Sciences

11 September 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32899231%20AND%20SRC:MED&resulttype=core&format=json

11 September 2020

volume

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32899231%20AND%20SRC:MED&resulttype=core&format=json

11 September 2020

issue

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32899231%20AND%20SRC:MED&resulttype=core&format=json

Creative Commons Attribution 4.0 International

11 September 2020

copyright license

start time

3 September 2020

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

COVID-19: the vasculature unleashed

1 reference

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7503392

Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention

21 October 2020

1 reference

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7503392

Clinical Characteristics of Coronavirus Disease 2019 in China

21 October 2020

1 reference

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7503392

Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area

21 October 2020

1 reference

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7503392

COVID-19: consider cytokine storm syndromes and immunosuppression

21 October 2020

1 reference

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7503392

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

21 October 2020

1 reference

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7503392

A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19

21 October 2020

1 reference

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7503392

Focus on Receptors for Coronaviruses with Special Reference to Angiotensin-converting Enzyme 2 as a Potential Drug Target - A Perspective

21 October 2020

1 reference

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7503392

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

21 October 2020

1 reference

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7503392

Wild-type human coronaviruses prefer cell-surface TMPRSS2 to endosomal cathepsins for cell entry

21 October 2020

1 reference

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7503392

COVID-19: towards understanding of pathogenesis

21 October 2020

1 reference

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7503392

COVID-19: immunopathology and its implications for therapy

21 October 2020

1 reference

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7503392

Clinical and immunological features of severe and moderate coronavirus disease 2019

21 October 2020

1 reference

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7503392

IL-6 Inhibitors in the Treatment of Serious COVID-19: A Promising Therapy?

21 October 2020

1 reference

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7503392

Cytokine storm and leukocyte changes in mild versus severe SARS-CoV-2 infection: Review of 3939 COVID-19 patients in China and emerging pathogenesis and therapy concepts

21 October 2020

1 reference

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7503392

Tocilizumab: A Therapeutic Option for the Treatment of Cytokine Storm Syndrome in COVID-19

21 October 2020

1 reference

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7503392

Tocilizumab for cytokine storm syndrome in COVID-19 pneumonia: an increased risk for candidemia?

21 October 2020

1 reference

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7503392

Current knowledge about the antivirals remdesivir (GS-5734) and GS-441524 as therapeutic options for coronaviruses

21 October 2020

1 reference

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7503392

Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8).

21 October 2020

1 reference

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7503392

Fatal cytokine release syndrome with chimeric anti-CD20 monoclonal antibody rituximab in a 71-year-old patient with chronic lymphocytic leukemia

21 October 2020

1 reference

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7503392

Covid-19 and thrombosis: what do we know about the risks and treatment?

21 October 2020

1 reference

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7503392

A SARS-CoV-2 protein interaction map reveals targets for drug repurposing

21 October 2020

1 reference

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7503392

Cytoprotective role of heme oxygenase-1 and heme degradation derived end products in liver injury

21 October 2020

1 reference

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7503392

Severe acute respiratory syndrome coronavirus ORF3a protein activates the NLRP3 inflammasome by promoting TRAF3-dependent ubiquitination of ASC

21 October 2020

1 reference

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7503392

Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure

21 October 2020

1 reference

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7503392

Heme oxygenase-1 and anti-inflammatory M2 macrophages

21 October 2020

1 reference

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7503392

Available Evidence and Ongoing Clinical Trials of Remdesivir: Could It Be a Promising Therapeutic Option for COVID-19?

21 October 2020

1 reference

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7503392

Remdesivir: Review of pharmacology, pre-clinical data and emerging clinical experience for COVID-19

21 October 2020

1 reference

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7503392

Remdesivir for the Treatment of Covid-19 — Final Report

21 October 2020

1 reference

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7503392

Test and treat COVID 65 plus - Hydroxychloroquine versus placebo in early ambulatory diagnosis and treatment of older patients with COVID19: A structured summary of a study protocol for a randomised controlled trial

21 October 2020

1 reference

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7503392

An evaluation of co-use of chloroquine or hydroxychloroquine plus azithromycin on cardiac outcomes: A pharmacoepidemiological study to inform use during the COVID19 pandemic

21 October 2020

1 reference

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7503392

Azithromycin and SARS-CoV-2 infection: where we are now and where we are going

21 October 2020

1 reference

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7503392

Safety considerations with chloroquine, hydroxychloroquine and azithromycin in the management of SARS-CoV-2 infection

21 October 2020

1 reference

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7503392

Safety use of hydroxychloroquine and its combination with azithromycin in the context of Sars-CoV-2 outbreak: Clinical experience in a Belgian tertiary center

21 October 2020

1 reference

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7503392

Additional safety consideration for azithromycin in the management of SARS-CoV-2 infection

21 October 2020

1 reference

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7503392

SARS-CoV-2 viral load and antibody responses: the case for convalescent plasma therapy

21 October 2020

1 reference

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7503392

Rapid recovery of a SARS-CoV-2 infected X-linked agammaglobulinemia patient after infusion of COVID-19 convalescent plasma

21 October 2020

1 reference

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7503392

Plasma from donors convalescent from SARS-CoV-2 infection-A matter of priorities

21 October 2020

1 reference

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7503392

Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trial

21 October 2020

1 reference

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7503392

Anti-SARS-CoV-2 virus antibody levels in convalescent plasma of six donors who have recovered from COVID-19

21 October 2020

1 reference

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7503392

Tocilizumab therapy in five solid and composite tissue transplant recipients with early ARDS due to SARS-CoV-2

21 October 2020

1 reference

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7503392

Tocilizumab Administration in Patients with SARS-CoV-2 Infection: Subcutaneous Injection versus Intravenous Infusion

21 October 2020

1 reference

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7503392

SARS-CoV-2 and COVID-19: is interleukin-6 (IL-6) the 'culprit lesion' of ARDS onset? What is there besides Tocilizumab? SGP130Fc

21 October 2020

1 reference

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7503392

Early use of tocilizumab in the prevention of adult respiratory failure in SARS-CoV-2 infections and the utilization of interleukin-6 levels in the management

21 October 2020

1 reference

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7503392

SARS-CoV-2: Recent Reports on Antiviral Therapies Based on Lopinavir/Ritonavir, Darunavir/Umifenovir, Hydroxychloroquine, Remdesivir, Favipiravir and Other Drugs for the Treatment of the New Coronavirus

21 October 2020

1 reference

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7503392

SARS-CoV-2 and HIV protease inhibitors: why lopinavir/ritonavir will not work for COVID-19 infection

21 October 2020

1 reference

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7503392

Lopinavir/ritonavir did not shorten the duration of SARS CoV-2 shedding in patients with mild pneumonia in Taiwan

21 October 2020

1 reference

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7503392

Lack of viral clearance by the combination of hydroxychloroquine and azithromycin or lopinavir and ritonavir in SARS-CoV-2-related acute respiratory distress syndrome

21 October 2020

1 reference

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7503392

Factors associated with prolonged viral shedding and impact of Lopinavir/Ritonavir treatment in hospitalised non-critically ill patients with SARS-CoV-2 infection

21 October 2020

1 reference

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7503392

Computational studies of drug repurposing and synergism of lopinavir, oseltamivir and ritonavir binding with SARS-CoV-2 Protease against COVID-19

21 October 2020

1 reference

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7503392

Comparison of hydroxychloroquine, lopinavir/ritonavir, and standard of care in critically ill patients with SARS-CoV-2 pneumonia: an opportunistic retrospective analysis

21 October 2020

1 reference

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7503392

The Australasian COVID-19 Trial (ASCOT) to assess clinical outcomes in hospitalised patients with SARS-CoV-2 infection (COVID-19) treated with lopinavir/ritonavir and/or hydroxychloroquine compared to standard of care: A structured summary of a stud

21 October 2020

1 reference

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7503392

Response to "Dose rationale for favipiravir use in patients infected with SARS-CoV-2"

21 October 2020

1 reference

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7503392

Dose rationale for favipiravir use in patients infected with SARS-CoV-2

21 October 2020

1 reference

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7503392

Continuous hydroxychloroquine or colchicine therapy does not prevent infection with SARS-CoV-2: Insights from a large healthcare database analysis

21 October 2020

1 reference

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7503392

COVID-19 and its implications for thrombosis and anticoagulation

21 October 2020

1 reference

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7503392

Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia

21 October 2020

1 reference

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7503392

Coagulation abnormalities and thrombosis in patients with COVID-19

21 October 2020

1 reference

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7503392

Venous Thrombosis Among Critically Ill Patients With Coronavirus Disease 2019 (COVID-19)

21 October 2020

1 reference

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7503392

Heme oxygenase-1 mediates the anti-inflammatory effect of interleukin-10 in mice

21 October 2020

1 reference

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7503392

Association among genetic polymorphisms of GSTP1, HO-1, and SOD-3 and chronic obstructive pulmonary disease susceptibility

21 October 2020

1 reference

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7503392

Heme Oxygenases in Cardiovascular Health and Disease

21 October 2020

1 reference

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7503392

Heme and HO-1 Inhibition of HCV, HBV, and HIV.

21 October 2020

1 reference

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7503392

Into the eye of the cytokine storm

21 October 2020

1 reference

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7503392

Heme oxygenase-1 protects airway epithelium against apoptosis by targeting the proinflammatory NLRP3-RXR axis in asthma

21 October 2020

1 reference

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7503392

ER stress-induced cell death mechanisms

21 October 2020

1 reference

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7503392

Severe Acute Respiratory Syndrome Coronavirus Viroporin 3a Activates the NLRP3 Inflammasome

21 October 2020

1 reference

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7503392

Severe acute respiratory syndrome-associated coronavirus 3a protein forms an ion channel and modulates virus release

21 October 2020

1 reference

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7503392

The ORF3a protein of SARS-CoV-2 induces apoptosis in cells

21 October 2020

1 reference

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7503392

SARS-Coronavirus Open Reading Frame-3a drives multimodal necrotic cell death

21 October 2020

1 reference

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7503392

Induction of heme oxygenase-1 expression inhibits platelet-dependent thrombosis

21 October 2020

1 reference

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7503392

Heme oxygenase-1 deficiency accelerates formation of arterial thrombosis through oxidative damage to the endothelium, which is rescued by inhaled carbon monoxide

21 October 2020

1 reference

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7503392

Genetic variation in heme oxygenase 1 (HMOX1) and the risk of recurrent venous thromboembolism

21 October 2020

1 reference

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7503392

Heme oxygenase-1 as a protective gene.

21 October 2020

1 reference

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7503392

Vascular heme oxygenase-1 induction suppresses microvascular thrombus formation in vivo

21 October 2020

1 reference

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7503392

Carbon monoxide inhibits capacitative calcium entry in human platelets

21 October 2020

1 reference

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7503392

Paradoxical rescue from ischemic lung injury by inhaled carbon monoxide driven by derepression of fibrinolysis

21 October 2020

1 reference

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7503392

Carbon monoxide and bile pigments: surprising mediators of vascular function

21 October 2020

1 reference

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7503392

Modulation of endothelial cell apoptosis by heme oxygenase-1-derived carbon monoxide

21 October 2020

1 reference

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7503392

Heme oxygenase-1-derived carbon monoxide enhances the host defense response to microbial sepsis in mice

21 October 2020

1 reference

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7503392

Carbon monoxide increases macrophage bacterial clearance through Toll-like receptor (TLR)4 expression.

21 October 2020

1 reference

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7503392

Biliverdin protects against polymicrobial sepsis by modulating inflammatory mediators

21 October 2020

1 reference

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7503392

Hemin inhibits NLRP3 inflammasome activation in sepsis-induced acute lung injury, involving heme oxygenase-1.

21 October 2020

1 reference

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7503392

IRG1 induced by heme oxygenase-1/carbon monoxide inhibits LPS-mediated sepsis and pro-inflammatory cytokine production

21 October 2020

1 reference

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7503392

Heme oxygenase-1-mediated autophagy protects against hepatocyte cell death and hepatic injury from infection/sepsis in mice

21 October 2020

1 reference

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7503392

The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs.

21 October 2020

1 reference

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7503392

The BET Bromodomain Inhibitor OTX015 Synergizes with Targeted Agents in Multiple Myeloma

21 October 2020

1 reference

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7503392

BRD4 and Cancer: going beyond transcriptional regulation

21 October 2020

1 reference

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7503392

Discovery of a Small-Molecule Degrader of Bromodomain and Extra-Terminal (BET) Proteins with Picomolar Cellular Potencies and Capable of Achieving Tumor Regression.

21 October 2020

1 reference

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7503392

Epigenetic drugs against cancer: an evolving landscape

21 October 2020

1 reference

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7503392

Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4.

21 October 2020

1 reference

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7503392

DRUG DEVELOPMENT. Phthalimide conjugation as a strategy for in vivo target protein degradation

21 October 2020

1 reference

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7503392

Promising in vivo efficacy of the BET bromodomain inhibitor OTX015/MK-8628 in malignant pleural mesothelioma xenografts

21 October 2020

1 reference

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7503392

Omacetaxine: a protein translation inhibitor for treatment of chronic myelogenous leukemia

21 October 2020

1 reference

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7503392

Pharmacology and therapeutic potential of sigma(1) receptor ligands

21 October 2020

1 reference

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7503392

The pharmacology of sigma-1 receptors

21 October 2020

1 reference

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7503392

Allosteric Modulators of Sigma-1 Receptor: A Review

21 October 2020

1 reference

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7503392

A Supercritical CO2 Extract of Neem Leaf (A. indica) and its Bioactive Liminoid, Nimbolide, Suppresses Colon Cancer in Preclinical Models by Modulating Pro-inflammatory Pathways.

21 October 2020

1 reference

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7503392

Antiangiogenic Effects and Therapeutic Targets of Azadirachta indica Leaf Extract in Endothelial Cells

21 October 2020

1 reference

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7503392

The Highly Pure Neem Leaf Extract, SCNE, Inhibits Tumorigenesis in Oral Squamous Cell Carcinoma via Disruption of Pro-tumor Inflammatory Cytokines and Cell Signaling

21 October 2020

1 reference

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7503392

Effects of Azardirachta indica on Vascular Endothelial Growth Factor and Cytokines in Diabetic Deep Wound

21 October 2020

1 reference

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7503392

Anti dermatophytic activity of Azardirachta indica (neem) by invitro study

21 October 2020

1 reference

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7503392

Therapeutics Role of Azadirachta indica (Neem) and Their Active Constituents in Diseases Prevention and Treatment

21 October 2020

1 reference

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7503392

Harnessing the anti-cancer natural product nimbolide for targeted protein degradation

21 October 2020

1 reference

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7503392

In vitro antiviral activity of neem (Azardirachta indica L.) bark extract against herpes simplex virus type-1 infection

21 October 2020

1 reference

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7503392

Inhibitory potential of neem (Azadirachta indica Juss) leaves on dengue virus type-2 replication

21 October 2020

1 reference

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7503392

The in vitro antiviral property of Azadirachta indica polysaccharides for poliovirus

21 October 2020

1 reference

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7503392

'In vitro' antiviral activity of neem (Azadirachta indica. A. Juss) leaf extract against group B coxsackieviruses.

21 October 2020

1 reference

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7503392

Water-extracted polysaccharides from Azadirachta indica leaves: Structural features, chemical modification and anti-bovine herpesvirus type 1 (BoHV-1) activity.

21 October 2020

1 reference

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7503392

Antiviral activity and mode of action of extracts from neem seed kernel against duck plague virus in vitro1.

21 October 2020

1 reference

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7503392

Medicinal properties of fractionated acetone/water neem [Azadirachta indica] leaf extract from Nigeria: a review.

21 October 2020

1 reference

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7503392

Novel molecular targets of Azadirachta indica associated with inhibition of tumor growth in prostate cancer

21 October 2020

1 reference

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7503392

A computational prediction of SARS-CoV-2 structural protein inhibitors from Azadirachta indica (Neem)

21 October 2020

1 reference

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7503392

Identification of a novel dual-target scaffold for 3CLpro and RdRp proteins of SARS-CoV-2 using 3D-similarity search, molecular docking, molecular dynamics and ADMET evaluation

21 October 2020

1 reference

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7503392

Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals

21 October 2020

1 reference

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7503392

SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness

21 October 2020

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=7503392

The Association of Interleukin-6 value, Interleukin inhibitors and Outcomes of Patients with COVID-19 in New York City

10 February 2021

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=7503392

Synergistic antiviral effect of hydroxychloroquine and azithromycin in combination against SARS-CoV-2: What molecular dynamics studies of virus-host interactions reveal

10 February 2021

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=7503392

Profiling COVID-19 pneumonia progressing into the cytokine storm syndrome: results from a single Italian Centre study on tocilizumab versus standard of care

10 February 2021

0 references

Identifiers

DOI

10.3390/IJMS21176412

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32899231%20AND%20SRC:MED&resulttype=core&format=json

11 September 2020

0 references

1 reference